RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan)

被引:56
作者
Nakazawa, T
Kondo, T
Kobayashi, Y
Takamura, N
Murata, S
Kameyama, K
Muramatsu, A
Ito, K
Kobayashi, M
Katoh, R
机构
[1] Univ Yamanashi, Dept Pathol, Interdisciplinary Grad Sch Med & Engn, Yamanashi 4093898, Japan
[2] Fuji Biomedix Co Ltd, Yamanashi, Japan
[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Epidemiol, Nagasaki, Japan
[4] Keio Univ Hosp, Div Pathol Diag, Tokyo, Japan
[5] Kofu Municipal Hosp, Div Surg, Yamanashi, Japan
[6] Ito Hosp, Div Surg, Tokyo, Japan
[7] Tokyo Womens Med Univ, Dept Pathol, Tokyo, Japan
关键词
Japanese; papillary thyroid carcinoma; RET rearrangement; patient age; reverse transcriptase-polymerase chain reaction;
D O I
10.1002/cncr.21270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The frequency of RET rearrangements (RET/PTC) in papillary thyroid carcinomas varies significantly according to geographic area, with the greatest incidence reported in the Belarus region, which is iodine- deficient and was contaminated severely after the Chernobyl reactor accident, and with the lowest incidence in iodine-rich, nonirradiated Japan. The authors investigated the prevalence of RET/PTC in a large number of thyroid tumors from Japanese patients. METHODS. Fresh and paraffin embedded tumor tissues from 215 Japanese patients were examined for RET rearrangements (RET/PTC1 and RET/PTC3) by means of reverse transcriptase-polymerase chain reaction analysis, with primers flanking the chimeric region, followed by direct-sequence analysis. RESULTS. RET/PTC was found only in papillary carcinomas and was not observed in other histologic types of thyroid tumors. The overall frequency of RET/PTC in papillary carcinomas was 28.4%, with a greater frequency in younger patients, including 41.9% of younger patients age < 20 years, 27.6% of patients age 20-40 years, and 24.8% of patients age > 40 years. Among the patients in these 3 age groups, the prevalence rate of RET/PTC1 was similar, but RET/PTC3 was observed most frequently among patients age < 20 years. When the tumors were grouped further according to histologic subtypes, the prevalence of RET/PTC3 was greater in solid/ solid -follicular papillary carcinomas than in classic papillary carcinomas. CONCLUSIONS. The results indicated that RET/PTC may be useful as a specific molecular marker for papillary thyroid carcinomas. Furthermore, its incidence in such tumors was not low in Japanese patients, and it seemed to be associated with patient age. Therefore, the current results raise questions regarding the belief that the frequency of RET/PTC differs geographically and is especially low in Japan.
引用
收藏
页码:943 / 951
页数:9
相关论文
共 43 条
[1]  
Bongarzone I, 1998, CLIN CANCER RES, V4, P223
[2]   Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma [J].
Bongarzone, I ;
Fugazzola, L ;
Vigneri, P ;
Mariani, L ;
Mondellini, P ;
Pacini, F ;
Basolo, F ;
Pinchera, A ;
Pilotti, S ;
Pierotti, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :2006-2009
[3]  
BONGARZONE I, 1994, CANCER RES, V54, P2979
[4]   High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation [J].
Bounacer, A ;
Wicker, R ;
Caillou, B ;
Cailleux, AF ;
Sarasin, A ;
Schlumberger, M ;
Suarez, HG .
ONCOGENE, 1997, 15 (11) :1263-1273
[5]   Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia [J].
Chua, EL ;
Wu, WM ;
Tran, KT ;
McCarthy, SW ;
Lauer, CS ;
Dubourdieu, D ;
Packham, N ;
O'Brien, CJ ;
Turtle, JR ;
Dong, QH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) :2733-2739
[6]  
Eng C, 1996, CANCER RES, V56, P2167
[7]  
EZAKI H, 1992, CANCER, V70, P808, DOI 10.1002/1097-0142(19920815)70:4<808::AID-CNCR2820700415>3.0.CO
[8]  
2-L
[9]   The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults [J].
Fenton, CL ;
Lukes, Y ;
Nicholson, D ;
Dinauer, CA ;
Francis, GL ;
Tuttle, RM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1170-1175
[10]  
FUGAZZOLA L, 1995, CANCER RES, V55, P5617